Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Transaminase Mutant. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN116064449A discloses stable transaminase mutants for bulky chiral amines. Enables green synthesis, cost reduction, and reliable supply for pharmaceutical intermediates.
Patent CN120718880A reveals high-efficiency biocatalysis for chiral amines. Achieve superior purity and reduced manufacturing costs with scalable enzyme technology.
Patent CN109609477B details a novel alpha-transaminase mutant enabling 100% conversion in L-glufosinate-ammonium synthesis, offering significant cost reduction and supply chain reliability for agrochemical manufacturers.
Novel transaminase mutant CN113621592A enables 99% yield of L-glufosinate. Reduces cost and improves supply chain reliability for agrochemical intermediates.
Patent CN119823960B discloses mutants for L-glufosinate. Improves efficiency and purity for agrochemical intermediate manufacturing supply chains.
Novel transaminase mutants for chiral amine production. Enhanced stability at 55°C and pH 10. Cost-effective biocatalysis for pharma intermediates.
Patent CN112094856B discloses high-efficiency transaminase mutants for sitagliptin synthesis, achieving >99.95% e.e. and enabling significant cost reduction in API manufacturing.
Patent CN108893455A details a transaminase mutant for L-glufosinate-ammonium production. Achieves 98% yield and 99% ee. Ideal for agrochemical intermediate supply chains seeking cost reduction.
Patent CN118374468B reveals mutant transaminase for high yield chiral amine intermediate production with improved stereoselectivity.
Patent CN120718880B reveals high-efficiency transaminase mutant for Cinacalcet intermediate synthesis offering significant cost and supply chain advantages.
Novel transaminase mutant enables high-yield sitagliptin intermediate synthesis with superior stereoselectivity and scalable biocatalytic process efficiency for global supply.
Patent CN113061594A details a robust immobilized transaminase process for sitagliptin intermediates, offering superior stability and simplified solvent systems for cost-effective API manufacturing.
Patent CN117660389A reveals mutant transaminase for chiral amines. Offers high conversion and purity for pharma and agrochemical manufacturing supply chains.
Patent CN108866021B details a novel transaminase mutant for synthesizing sitagliptin intermediates with >99% ee. Discover cost-effective biocatalytic solutions for API manufacturing.
Patent CN110540975B reveals high-efficiency biocatalytic route for sitagliptin precursors, offering superior stereoselectivity and reduced environmental impact for pharma supply chains.
Patent CN121495896A reveals enhanced enzyme catalysis for chiral amine synthesis offering significant cost reduction and supply chain reliability for agrochemical manufacturing.